Advanced

Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - Clinical associations and reasons for discrepancies

Chebil, G; Bendahl, Pär-Ola LU ; Idvall, Ingrid LU and Fernö, Mårten LU (2003) In Acta Oncologica 42(7). p.719-725
Abstract
Estrogen ( ER) and progesterone receptor (PgR) status was analysed in paraffin-embedded breast cancer material with immunohistochemical (IHC) technique and compared with corresponding analyses in cytosols ( CYT). ER showed the same status (positive/negative) with both methods in 88% of the samples (352/ 402). The concordance was also high for PgR status (81% [321/394]). Besides values near cut-off, heterogeneity in the distribution of receptor positive and negative nuclei within a tumour sample was the main reason for discordances. Histological type, presence of sclerosis, necrosis and non-invasive cells, and technical artefacts seem to be of only limited importance for explaining discordances. All patients have been treated with adjuvant... (More)
Estrogen ( ER) and progesterone receptor (PgR) status was analysed in paraffin-embedded breast cancer material with immunohistochemical (IHC) technique and compared with corresponding analyses in cytosols ( CYT). ER showed the same status (positive/negative) with both methods in 88% of the samples (352/ 402). The concordance was also high for PgR status (81% [321/394]). Besides values near cut-off, heterogeneity in the distribution of receptor positive and negative nuclei within a tumour sample was the main reason for discordances. Histological type, presence of sclerosis, necrosis and non-invasive cells, and technical artefacts seem to be of only limited importance for explaining discordances. All patients have been treated with adjuvant tamoxifen for two years. The two subgroups, which were ERCYT+/ ERIHC+ or ERCYT-/ERIHC+, both had a significantly better progression-free survival (PFS; median follow-up: almost 6 years) than the ERCYT -/ERIHC- group (p< 0.001 and p = 0.007, respectively). The remaining group, ERCYT+/ERIHC-, had an intermediate PFS. For PgR, the associations with PFS were weaker, with significantly better PFS than the PgR(CYT)-/PgR(IHC)- group being found only for the PgR(CYT)+/PgR(IHC) - group (p = 0.03). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
42
issue
7
pages
719 - 725
publisher
Taylor & Francis
external identifiers
  • wos:000186273900007
  • pmid:14690157
  • scopus:0345017798
ISSN
1651-226X
DOI
10.1080/02841860310011023
language
English
LU publication?
yes
id
3531e5d3-bafd-4bbb-8d85-24b89ee70a1d (old id 297437)
date added to LUP
2007-08-28 14:58:44
date last changed
2018-01-07 09:24:53
@article{3531e5d3-bafd-4bbb-8d85-24b89ee70a1d,
  abstract     = {Estrogen ( ER) and progesterone receptor (PgR) status was analysed in paraffin-embedded breast cancer material with immunohistochemical (IHC) technique and compared with corresponding analyses in cytosols ( CYT). ER showed the same status (positive/negative) with both methods in 88% of the samples (352/ 402). The concordance was also high for PgR status (81% [321/394]). Besides values near cut-off, heterogeneity in the distribution of receptor positive and negative nuclei within a tumour sample was the main reason for discordances. Histological type, presence of sclerosis, necrosis and non-invasive cells, and technical artefacts seem to be of only limited importance for explaining discordances. All patients have been treated with adjuvant tamoxifen for two years. The two subgroups, which were ERCYT+/ ERIHC+ or ERCYT-/ERIHC+, both had a significantly better progression-free survival (PFS; median follow-up: almost 6 years) than the ERCYT -/ERIHC- group (p&lt; 0.001 and p = 0.007, respectively). The remaining group, ERCYT+/ERIHC-, had an intermediate PFS. For PgR, the associations with PFS were weaker, with significantly better PFS than the PgR(CYT)-/PgR(IHC)- group being found only for the PgR(CYT)+/PgR(IHC) - group (p = 0.03).},
  author       = {Chebil, G and Bendahl, Pär-Ola and Idvall, Ingrid and Fernö, Mårten},
  issn         = {1651-226X},
  language     = {eng},
  number       = {7},
  pages        = {719--725},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - Clinical associations and reasons for discrepancies},
  url          = {http://dx.doi.org/10.1080/02841860310011023},
  volume       = {42},
  year         = {2003},
}